Randomized phase II trial of the anti-angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory

Author： Miller Kathy  

Publisher： Springer Publishing Company

ISSN： 0167-6806

Source： Breast Cancer Research and Treatment, Vol.89, Iss.2, 2005-01, pp. : 187-197

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Salvage chemotherapy with docetaxel and pegylated liposomal doxorubicin in pretreated patients with platinum- and taxane-sensitive ovarian cancer: a multicenter phase II trial of the Hellenic Oncology Research Group (HORG)

By Koinis Filippos   Polyzos Aristidis   Christopoulou Athina   Zafeiriou Zafeiris   Emmanouilidis Christos   Papadimitraki Elisavet   Kalykaki Antonia   Kalbakis Kostas   Samonis George   Georgoulias Vassilis  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 4, 2014-04 ,pp. : 819-825

Springer Publishing Company

Access to resources Recommend Favorite

Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer

By Wildiers H.  

Breast Cancer Research and Treatment, Vol. 123, Iss. 2, 2010-09 ,pp. : 463-469

Springer Publishing Company

Access to resources Recommend Favorite

A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients

By Pierga Jean-Yves   Delaloge Suzette   Espié Marc   Brain Etienne   Sigal-Zafrani Brigitte   Mathieu Marie-Christine   Bertheau Philippe   Guinebretière Jean   Spielmann Marc   Savignoni Alexia   Marty Michel  

Breast Cancer Research and Treatment, Vol. 122, Iss. 2, 2010-07 ,pp. : 429-437

Springer Publishing Company

Access to resources Recommend Favorite

Phase II Trial of Neoadjuvant Chemotherapy with Docetaxel Followed by Epirubicin in Stage II/III Breast Cancer

By Ramaswamy Bhuvaneswari   Povoski Steven   Rhoades Chris   Allen Joan   Hauger Marsha   Young Donn   Burak William   Farrar William   Yee Lisa   Kendra Kari   Somasundaram Sivagurunathan   Orlowski Robert   Shapiro Charles  

Breast Cancer Research and Treatment, Vol. 93, Iss. 1, 2005-09 ,pp. : 67-74

Springer Publishing Company

Access to resources Recommend Favorite

A Southwest Oncology Group Randomized Phase II Study of Doxorubicin and Paclitaxel as Frontline Chemotherapy for Women with Metastatic Breast Cancer

By Lyman Gary   Green Stephanie   Ravdin Peter   Geyer Charles   Russell Christy   Balcerzak Stanley   Thomas Budd G.   Martino Silvana  

Breast Cancer Research and Treatment, Vol. 85, Iss. 2, 2004-05 ,pp. : 143-150

Springer Publishing Company

Access to resources Recommend Favorite